VRTX - CIK 0000875320
VERTEX PHARMACEUTICALS INC / MA trades as VRTX and has a market capitalization of $110.46 B, making it the #136 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $12.00B, up 8.9% from the prior year and net income of $3.95B. This page tracks VERTEX PHARMACEUTICALS INC / MA through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years VERTEX PHARMACEUTICALS INC / MA's revenue grew from $1.70B to $12.00B, a compound annual growth rate of 24.2%. Net profit margin expanded from -6.6% to 32.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| S-8 POS | - | 2026-05-13 |
Total revenue increased 12% to $2.96 billion compared to the second quarter of 2024, primarily driven by the continued performance of cystic ...
Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY. At the ...
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results ; FY 2026 ; Total revenue. $12.95 to $13.1 billion ; Non-CF product revenue.
Total revenue of $2.77 billion , a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new ...
Total revenue increased 11% to $3.08 billion compared to the third quarter of 2024, primarily driven by the continued performance of cystic ...
The largest companies sharing VERTEX PHARMACEUTICALS INC / MA's SEC industry classification (pharmaceutical preparations).
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a market capitalization of $110.46 B as of 2026-06-10, ranking #136 among US-listed companies.
VERTEX PHARMACEUTICALS INC / MA reported revenue of $12.00B for fiscal year 2025, an increase of 8.9% year over year.
Yes. VERTEX PHARMACEUTICALS INC / MA reported net income of $3.95B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.